Microenvironmental Niches and Sanctuaries: A Route to Acquired Resistance.

A tumor vasculature that is functionally abnormal results in irregular gradients of metabolites and drugs within the tumor tissue. Recently, significant efforts have been committed to experimentally examine how cellular response to anti-cancer treatments varies based on the environment in which the cells are grown. In vitro studies point to specific conditions in which tumor cells can remain dormant and survive the treatment. In vivo results suggest that cells can escape the effects of drug therapy in tissue regions that are poorly penetrated by the drugs. Better understanding how the tumor microenvironments influence the emergence of drug resistance in both primary and metastatic tumors may improve drug development and the design of more effective therapeutic protocols. This chapter presents a hybrid agent-based model of the growth of tumor micrometastases and explores how microenvironmental factors can contribute to the development of acquired resistance in response to a DNA damaging drug. The specific microenvironments of interest in this work are tumor hypoxic niches and tumor normoxic sanctuaries with poor drug penetration. We aim to quantify how spatial constraints of limited drug transport and quiescent cell survival contribute to the development of drug resistant tumors.

[1]  M. Heymann,et al.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets , 2011, Sarcoma.

[2]  M. Gottesman,et al.  The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance , 2013 .

[3]  William Pao,et al.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells , 2015, Cancer informatics.

[4]  Jeff Gore,et al.  Turning ecology and evolution against cancer , 2014, Nature Reviews Cancer.

[5]  M. Bui,et al.  Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. , 2015, Medical hypotheses.

[6]  Gibin G Powathil,et al.  Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. , 2012, Journal of theoretical biology.

[7]  F. Baquero,et al.  Ecology and Evolution as Targets: the Need for Novel Eco-Evo Drugs and Strategies To Fight Antibiotic Resistance , 2011, Antimicrobial Agents and Chemotherapy.

[8]  Ying Zhang Persisters, persistent infections and the Yin–Yang model , 2014, Emerging Microbes & Infections.

[9]  M. Gottesman,et al.  The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[10]  Mina J. Bissell,et al.  The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.

[11]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[12]  A. Pisco,et al.  Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.

[13]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[14]  P. Karran Mechanisms of tolerance to DNA damaging therapeutic drugs. , 2001, Carcinogenesis.

[15]  Geoffrey R Oxnard,et al.  The cellular origins of drug resistance in cancer , 2016, Nature Medicine.

[16]  A. Koong,et al.  Pancreatic tumors show high levels of hypoxia. , 2000, International journal of radiation oncology, biology, physics.

[17]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[18]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[19]  Junjie Chen,et al.  DNA damage tolerance: a double-edged sword guarding the genome. , 2013, Translational cancer research.

[20]  T. Schacker,et al.  Overcoming pharmacologic sanctuaries , 2013, Current opinion in HIV and AIDS.

[21]  R. Kaplan,et al.  Niche-to-niche migration of bone-marrow-derived cells. , 2007, Trends in molecular medicine.

[22]  P. Steeg,et al.  The Biology of Metastasis to a Sanctuary Site , 2007, Clinical Cancer Research.

[23]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[24]  Martin A. Nowak,et al.  Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy , 2014, PLoS Comput. Biol..

[25]  K. Cimprich,et al.  DNA damage tolerance: when it's OK to make mistakes. , 2009, Nature chemical biology.

[26]  J. Bigger Synergic action of penicillin and sulphathiazole on Bacterium typhosum. , 1946, Lancet.

[27]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.

[28]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[29]  E. Friedberg Suffering in silence: the tolerance of DNA damage , 2005, Nature Reviews Molecular Cell Biology.

[30]  Katarzyna A Rejniak,et al.  Limiting the Development of Anti-Cancer Drug Resistance in a Spatial Model of Micrometastases , 2016, bioRxiv.

[31]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[32]  G. Giaever,et al.  DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. , 2013, Chemistry & biology.

[33]  L. Kleinberg,et al.  Unsanctifying the sanctuary: challenges and opportunities with brain metastases. , 2015, Neuro-oncology.

[34]  Zhenyu Jin,et al.  Bacteria differently deploy type-IV pili on surfaces to adapt to nutrient availability , 2016, npj Biofilms and Microbiomes.

[35]  Dominik Wodarz,et al.  Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. , 2007, Theoretical population biology.

[36]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[37]  Chih-kuan Tung,et al.  Acceleration of Emergence of Bacterial Antibiotic Resistance in Connected Microenvironments , 2011, Science.

[38]  Orkun S. Soyer,et al.  Bacterial Drug Tolerance under Clinical Conditions Is Governed by Anaerobic Adaptation but not Anaerobic Respiration , 2014, Antimicrobial Agents and Chemotherapy.

[39]  Mark A. J. Chaplain,et al.  Towards Predicting the Response of a Solid Tumour to Chemotherapy and Radiotherapy Treatments: Clinical Insights from a Computational Model , 2013, PLoS Comput. Biol..

[40]  Denis Wirtz,et al.  Hypoxia and the extracellular matrix: drivers of tumour metastasis , 2014, Nature Reviews Cancer.

[41]  H M Byrne,et al.  A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.

[42]  Robert A Gatenby,et al.  A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.

[43]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[44]  Miles A. Miller,et al.  Advances in measuring single-cell pharmacology in vivo. , 2015, Drug discovery today.

[45]  Damien J. Ferraro,et al.  Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.

[46]  Maciej Swat,et al.  Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. , 2015, Seminars in cancer biology.

[47]  Mary Ellen Wiltrout,et al.  Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance , 2009, Microbiology and Molecular Biology Reviews.

[48]  Vittorio Cristini,et al.  Understanding Drug Resistance in Breast Cancer with Mathematical Oncology , 2014, Current Breast Cancer Reports.

[49]  B. Baguley Multiple Drug Resistance Mechanisms in Cancer , 2010, Molecular biotechnology.

[50]  Greg M. Thurber,et al.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.

[51]  W. Nierman,et al.  The In vitro Antibiotic Tolerant Persister Population in Burkholderia pseudomallei is Altered by Environmental Factors , 2015, Front. Microbiol..

[52]  Zahra Aminzare,et al.  Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model , 2014, 1412.0780.

[53]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[55]  Robert H. Austin,et al.  An analogy between the evolution of drug resistance in bacterial communities and malignant tissues , 2011, Nature Reviews Cancer.

[56]  M. Barcellos-Hoff,et al.  The evolution of the cancer niche during multistage carcinogenesis , 2013, Nature Reviews Cancer.

[57]  S. Carr,et al.  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.

[58]  W. Dalton,et al.  The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.

[59]  S. Menchón The Effect of Intrinsic and Acquired Resistances on Chemotherapy Effectiveness , 2015, Acta Biotheoretica.

[60]  L. Vermeulen,et al.  Cancer stem cell niche: the place to be. , 2011, Cancer research.

[61]  Cyrus M. Ghajar Metastasis prevention by targeting the dormant niche , 2015, Nature Reviews Cancer.

[62]  K. Lewis Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[63]  B. Perthame,et al.  Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.

[64]  Doron Levy,et al.  The dynamics of drug resistance: a mathematical perspective. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[65]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[66]  R. Bristow,et al.  Tumor hypoxia as a driving force in genetic instability , 2013, Genome Integrity.

[67]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.